Does the donor matter? Donor vs patient effects in the outcome of a next-generation microbiota-based drug trial for recurrent Clostridium difficile infection

Future Microbiology

Volumn 11, Issue 5, 2016, Pages 611-616

  Ray, Arnab ^a   Jones, Courtney ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b Rebiotix Inc   (United States)

Author keywords

Clostridium difficile infection; Fecal microbiota transplant; Fecal transplantation; FMT; FT; Gut microbiota; RBX2660; Stool donor

Indexed keywords

ADULT; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; DONOR; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMAN; INTESTINE FLORA; MALE; MICROBIOLOGY; MIDDLE AGED; PATIENT; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; SPECIES DIFFERENCE; TREATMENT OUTCOME;

ADULT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MIDDLE AGED; PATIENTS; SPECIES SPECIFICITY; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84970038889     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.16.10     Document Type: Article

References (14)

1. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53(10), 994-1002 (2011).
2. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and metaanalysis. Am. J. Gastroenterol. 108(4), 500-508 (2013).
3. Keller JJ, Kuijper EJ. Treatment of recurrent and severe Clostridium difficile infection. Annu. Rev. Med. 66, 373-386 (2015).
4. Van Nood E, Speelman P, Nieuwdorp M, Keller J. Fecal microbiota transplantation. facts and controversies. Curr. Opin. Gastroenterol. 30(1), 34-39 (2014).
5. Lee CH, Belanger JE, Kassam Z et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur. J. Clin. Microbiol. Infect. Dis. 33(8), 1425-1428 (2014).
6. Youngster I, Sauk J, Pindar C et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin. Infect. Dis. 58(11), 1515-1522 (2014).
7. Ray A, Smith R, Breaux J. Fecal microbiota transplantation for Clostridium difficile infection: the Ochsner experience. Ochsner J. 14(4), 538-544 (2014).
8. Brandt LJ. American Journal of Gastroenterology lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am. J. Gastroenterol. 108(2), 177-185 (2013).
9. Orenstein R, Dubberke E, Hardi R et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin. Infect. Dis. 62(5), 596-602 (2016).
10. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch. Intern. Med. 172(2), 191-193 (2012).
11. Kassam Z, Lee CH. Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin. Lab. Med. 34(4), 787-798 (2014).
12. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 107 (5), 761-767 (2012).
13. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther. Adv. Gastroenterol. 5(6), 403-420 (2012).
14. Satokari R, Mattila E, Kainulainen V, Arkkila PE. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection -an observational cohort study. Ailment. Pharmacol. Ther. 41(1) 46-53 (2015).